News | June 13, 2014

Cardinal Health Ships 2 Millionth Mynx Vascular Closure Device

Company celebrates milestone after recent acquisition of AccessClosure

Mynx Vascular Closure Device Cardinal Health 2 Millionth Shipment June 2014

June 13, 2014 — Cardinal Health announced the 2 millionth shipment of the Mynx Vascular Closure Device (VCD). The Mynx product family of vascular closure devices combines the reliability of an easy-to-use deployment system with the security of mechanical closure and the safety of an extravascular sealant that enables physicians to seal an arteriotomy securely without leaving anything permanently behind in the artery.

“There are several vascular closure devices on the market, but most of them leave material behind, either inside the femoral artery, like a plug, or material in the arterial wall, like a suture or clip, which limits their use in certain situations,” said Najam Wasty, director of invasive cardiovascular laboratory and director of Interventional Cardiology Fellowship Training Program at a major teaching institution. “The major advantage of the Mynx VCD is that it is extravascular. In other words, it does not leave any materials permanently inside the artery or in the wall of the artery. Many physicians find this feature attractive since it allows safe use of the Mynx VCD in most situations.”

The first Mynx Vascular Closure Device received U.S. Food and Drug Administration (FDA) approval in May 2007. The Mynx product family includes the new Mynx Ace Vascular Closure Device, launched in 2013 in the United States, and the MynxGrip Vascular Closure Device, launched in 2012. Mynx devices use proprietary Grip Technology, which employs an extravascular sealant that actively adheres to the artery for safe and secure mechanical closure and dissolves within 30 days, leaving nothing permanently behind in the healed artery.  

Cardinal Health completed its acquisition of AccessClosure in May.

The Mynx product family is clinically proven and has been featured in several peer-reviewed articles.

For more information:

Related Content

Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.
Technology | Vascular Closure Devices | December 14, 2017
Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices | October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices | September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
Overlay Init